The Argentine Society of Rheumatology (SAR) set out to develop a national register of patients with rheumatic diseases who have received a SARS-CoV-2 vaccine in order to assess their efficacy and safety in this population.
This is an observational, longitudinal, multicenter study, including patients with rheumatic diseases who have been vaccinated for COVID-19 in Argentine or any country. Patients will be followed for 12 months and two evaluations will be performed, one at baseline and the other after the follow-up time is completed. The aim of this registry is to evaluate the efficacy and safety of the SARS-CoV-2 vaccines in patients with rheumatic diseases.
Patients with rheumatic diseases who have been vaccinated for COVID-19
Buenos Aires, Buenos Aires F.D., Argentina
Guillermo Posn-Estel, PhD · unisar@reumatologia.org.ar · +5493412644125
Buenos Aires, Argentina
Carolina Isnardi, MD · carolina.isnardi@reumatologia.org.ar · 1169583394